Comment
Bevacizumab (Avastin, Genentech, Inc., South San Francisco, CA, USA) is a full-length recombinant humanized antibody against all isoforms of VEGF-A. We report the short-term results of intravitreal bevacizumab treatment on choroidal metastases of colon adenocarcinoma in a patient. In his first eye the tumour progressed, whereas in the second eye it regressed. There is no report on successful treatment of choroidal metastasis in one eye but failure in the other eye with intravitreal bevacizumab.
The mechanisms for the response are the antiangiogenic and antipermeability effects of bevacizumab on new tumour vessels and smaller lesions. The massive exudation that hinders bevacizumab from reaching the metastatic tumour may explain the nonresponse.
Manzano et al 1 found bevacizumab not toxic to the retina at a concentration of 2.5 mg in rabbits. The safe dosage of intravitreal bevacizumab is presumed to be 7.5 mg in humans. Therefore, Amselem et al 2 chose 4 mg bevacizumab for choroidal metastasis secondary to breast carcinoma. Kuo et al 3 reported successful short-term regression treated with three monthly injections of 1.25 mg. In our case, 4 mg was used in First, the authors calculate a total score from all questions in the PalmPilot-VFQ. However, a fundamental criterion underlying the Rasch models is unidimensionality. Unidimensionality refers to all items contributing to the measurement of a single underlying trait. 2 Although unidimensionality can be assessed by fit statistics as has been performed by the authors, recent studies suggest that these alone are inadequate and recommend performing principal components analysis (PCA) of the residuals for a detailed evidence of dimensionality. 3 It is crucial to establish unidimensionality because in its absence, the user will always be uncertain regarding the underlying latent trait being measured in a questionnaire. Reporting a total questionnaire score is invalid in such a scenario. Consider a multidimensional clinical measure derived by combining visual acuity and IOP values to form a clinical score from 0 to 100. Although this may save time in the clinic, the output is of no use as it conveys no meaning. With recent studies suggesting that the NEIVFQ measures not QOL but visual functioning, establishing the underlying latent trait in this popular questionnaire assumes greater significance. 4 Therefore, researchers should perform a PCA of residuals to establish unidimensionality (or lack of unidimensionality thereof) during assessment of questionnaires.
Second, the authors have not examined the validity of the subscales of PalmPilot-VFQ. The present analyses were limited to assessing the NEIVFQ-25 as a single overall measurement. It is important to investigate the validity of subscales because the validity of an overall scale does not imply valid subscales. Usually the subscales have fewer items and so it is not uncommon to come across subscales that lack precision for meaningful measurement. 5 The precision, perhaps reported with person separation, should be reported for each subscale.
The initiative to develop a PalmPilot-VFQ is laudable, and with a fuller description of the psychometric properties, particularly unidimensionality and precision of the subscales, the PalmPilot-VFQ may improve the implementation of PRO measurement.
